Novo Nordisk, Cellartis and Lund University in collaboration
Novo Nordisk A/S, Cellartis AB, and Lund University Stem Cell Center have signed a collaborative research agreement for the development of insulin-producing cells from human stem cells. The collaboration aims to develop a cell therapy for the treatment of insulin-dependent diabetes and, in the longer term, a cure for diabetes.
Under the terms of the agreement Novo Nordisk acquires the exclusive rights to further develop and commercialise potential products for the treatment of diabetes, while Cellartis acquires the exclusive rights to further develop and commercialise certain other products resulting from the technologies developed under the collaboration.